A phase II pilot study investigating the efficacy and activity of single agent GM-CSF (Leukine) maintenance approach in androgen-independent prostate cancer (AIPC) patients responding to Taxotere chemotherapy

Trial Profile

A phase II pilot study investigating the efficacy and activity of single agent GM-CSF (Leukine) maintenance approach in androgen-independent prostate cancer (AIPC) patients responding to Taxotere chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Sargramostim (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Sep 2007 End date updated from NCT.
    • 16 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top